MX2021008605A - Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado. - Google Patents

Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado.

Info

Publication number
MX2021008605A
MX2021008605A MX2021008605A MX2021008605A MX2021008605A MX 2021008605 A MX2021008605 A MX 2021008605A MX 2021008605 A MX2021008605 A MX 2021008605A MX 2021008605 A MX2021008605 A MX 2021008605A MX 2021008605 A MX2021008605 A MX 2021008605A
Authority
MX
Mexico
Prior art keywords
solid tumor
antibodies
cell death
tumor cancers
programmed cell
Prior art date
Application number
MX2021008605A
Other languages
English (en)
Spanish (es)
Inventor
Karl Hsu
Ugur Sahin
Robert Jabulowsky
Friederike Gieseke
Timothy R Wagenaar
Serena Masciari
Semra Yoruk
Nicolas Acquavella
Marie Bernardo
Zuzana Jiracova TRNKOVA
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021008605A publication Critical patent/MX2021008605A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021008605A 2019-01-21 2020-01-17 Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado. MX2021008605A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962794896P 2019-01-21 2019-01-21
US201962926379P 2019-10-25 2019-10-25
EP19306471 2019-11-14
PCT/US2020/014039 WO2020154189A1 (en) 2019-01-21 2020-01-17 Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers

Publications (1)

Publication Number Publication Date
MX2021008605A true MX2021008605A (es) 2021-10-26

Family

ID=69582159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008605A MX2021008605A (es) 2019-01-21 2020-01-17 Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado.

Country Status (13)

Country Link
US (1) US20220288199A1 (https=)
EP (1) EP3914355A1 (https=)
JP (1) JP2022518236A (https=)
KR (1) KR20210118870A (https=)
CN (1) CN113507963A (https=)
AU (1) AU2020210614A1 (https=)
BR (1) BR112021013965A2 (https=)
CA (1) CA3126110A1 (https=)
IL (1) IL284645A (https=)
MX (1) MX2021008605A (https=)
SG (1) SG11202107396RA (https=)
TW (1) TWI850316B (https=)
WO (1) WO2020154189A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428301A (zh) 2017-02-28 2024-07-16 法商賽諾菲公司 治療性rna
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
SG11202106764YA (en) 2018-12-27 2021-07-29 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020154187A1 (en) * 2019-01-21 2020-07-30 Sanofi Therapeutic rna for advanced stage solid tumor cancers
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN116194142A (zh) 2020-09-03 2023-05-30 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症疼痛的方法
WO2022090203A1 (en) * 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
EP4232068A1 (en) * 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
WO2023279068A1 (en) * 2021-07-02 2023-01-05 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
EP4261217A4 (en) 2022-02-28 2024-09-11 Guangzhou Henovcom Bioscience Co., Ltd. Compound for rna capping and application of compound
CN115260264B (zh) * 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
US10131712B2 (en) * 2012-08-14 2018-11-20 Ibc Pharmaceuticals, Inc. Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CN109715205A (zh) * 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
TW202428301A (zh) * 2017-02-28 2024-07-16 法商賽諾菲公司 治療性rna
JP2020514370A (ja) * 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤
WO2020154187A1 (en) * 2019-01-21 2020-07-30 Sanofi Therapeutic rna for advanced stage solid tumor cancers

Also Published As

Publication number Publication date
SG11202107396RA (en) 2021-08-30
EP3914355A1 (en) 2021-12-01
CA3126110A1 (en) 2020-07-30
TWI850316B (zh) 2024-08-01
BR112021013965A2 (pt) 2021-09-21
CN113507963A (zh) 2021-10-15
KR20210118870A (ko) 2021-10-01
US20220288199A1 (en) 2022-09-15
IL284645A (en) 2021-08-31
TW202043274A (zh) 2020-12-01
WO2020154189A1 (en) 2020-07-30
JP2022518236A (ja) 2022-03-14
AU2020210614A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
MX2021008605A (es) Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado.
MX2024013523A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
WO2020227159A8 (en) Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
MX2022007140A (es) Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3).
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2025005315A (es) Celulas t para usarse en el tratamiento de una enfermedad o afeccion
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
WO2018094190A3 (en) Gut microbiota and treatment of cancer
EA202091539A1 (ru) Комбинированная терапия против злокачественной опухоли антагонистом iap и молекулой против pd-1
MY202377A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
BR112021008549A2 (pt) Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EP4378530A3 (en) Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody
MX2018010508A (es) Preparaciones mejoradas de celulas progenitoras hepaticas adultas.
MX2021008604A (es) Arn terapeutico para tumores solidos cancerigenos en etapa avanzada.
Terme et al. NK cells from pleural effusions are potent antitumor effector cells
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
MX2020004960A (es) Asociacion de activos para tratar el cancer de prostata.
AU2018314227A8 (en) Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus
ZA201907369B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
Kochenderfer et al. Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous T cells genetically-engineered to express an anti-CD19 chimeric antigen receptor
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2021013351A (es) Terapias de combinacion.
WO2021062085A8 (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies